Age specific prostate specific antigen reference ranges: Population specific

Journal of Urology

Volumn 159, Issue 2, 1998, Pages 444-448

  Borer, Joseph G ^a   Sherman, Joel ^a   Solomon, Michael C ^a   Plawker, Marc W ^a   Macchia, Richard J ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Age factors; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER DIAGNOSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SCORING SYSTEM; STANDARD;

EID: 0031974497     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63945-4     Document Type: Article

References (23)

1. Oesterling, J. E., Jacobsen, S. J., Chute, C. G., Guess, H. A., Girman, C. J., Panser, L. A. and Lieber, M. M.: Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. J.A.M.A., 270: 860, 1993.
2. Dalkin, B. L., Ahmann, F. R. and Kopp, J. B.: Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J. Urol., 150: 1837, 1993.
3. Collins, G. N., Lee, R. J., McKelvie, G. B., Rogers, A. C. N. and Hehir, M.: Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Brit. J. Urol., 71: 445, 1993.
4. Anderson, J. R., Strickland, D., Corbin, D., Byrnes, J. A. and Zweiback, E.: Age specific reference ranges for serum prostate-specific antigen. Urology, 46: 54, 1995.
5. Crawford, E. D., DeAntoni, E. P., Stone, N. N., Blum, D. S., Berger, E. R., Gambert, S. R., Staggers, F. M. and Eisenberger, M. A.: Prostate cancer awareness week demonstrates continued value to early detection strategies. J. Urol., part 2, 153: 312A, abstract 334, 1995.
6. Imai, K., Ichinose, Y., Kubota, Y., Yamanaka, H. and Sato, J.: Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer. J. Urol., 154: 1085, 1995.
7. Partin, A. W. and Oesterling, J. E.: Prostate-specific antigen in clinical urologic practice. AUA Update Series, 14: 1, 1995.
8. Catalona, W. J., Hudson, M. A., Scardino, P. T., Richie, J. P., Ahmann, F. R., Flanigan, R. C., deKernion, J. B., Ratlif, T. L., Kavoussi, L. R., Dalkin, B. L., Waters, W. B., MacFarlane, M. T. and Southwick, P. C.: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J. Urol., 152: 2037, 1994.
9. Babaian, R. J., Kojima, M. and Ramirez, E. I.: Prostate specific antigen (PSA) density and age-referenced PSA versus PSA alone in early detection of prostate cancer: M. D. Anderson cancer center experience. J. Urol., part 2, 153: 419A, abstract 761, 1995.
10. Petteway, J. and Brawer, M. K.: Age specific vs. 4.0 ng/ml as a PSA cutoff in the screening population: impact on cancer detection. J. Urol., part 2, 153: 465A, abstract 946, 1995.
11. Weichert-Jacobsen, K. and Loch, T.: Clinical significance of prostate specific antigen age-specific reference ranges. J. Urol., part 2, 153: 465A, abstract 945, 1995.
12. El-Galley, R. E. S., Petros, J. A., Sanders, W. H., Keane, T. E., Galloway, N. T. M., Cooner, W. H. and Graham, S. D.: Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urology, 46: 200, 1995.
13. Reissigl, A., Pointner, J., Horninger, W., Ennemoser, O., Strasser, H., Klocker, H. and Bartsch, G.: Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. Urology, 46: 662, 1995.
14. Oesterling, J. E., Jacobsen, S. J. and Cooner, W. H.: The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J. Urol., 153: 1160, 1995.
15. Partin, A. W., Criley, S. R., Subong, E. N. P., Zincke, H., Walsh, P. C. and Oesterling, J. E.: Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: a pathological analysis. J. Urol., 155: 1336, 1996.
16. Meshref, A. W., Bazinet, M., Trudel, C., Aronson, S., Peloquin, F., Nachabe, M., Dessureault, J., Aprikian, A. G., Begin, L. R. and Elhilali, M. M.: Role of prostate-specific antigen density after applying age-specific prostate-specific antigen reference ranges. Urology, 45: 972, 1995.
17. Epstein, J. I., Walsh, P. C., Carmichael, M. and Brendler, C. B.: Pathologic and clinical findings to predict tumor extent of nonpalpable (Stage T1c) prostate cancer. J.A.M.A., 271: 368, 1994.
18. Menta, C. and Patel, N.: Stat Xact: Statistical Software for Exact Nonparametric Inference. Cambridge, Massachusetts: Cytel Software Corp., 1991.
19. Oesterling, J. E.: Using prostate-specific antigen to eliminate unnecessary diagnostic tests: significant worldwide economic implications. Urology, suppl. 3A, 46: 26, 1995.
20. Morgan, T. O., Jacobsen, S. J., McCarthy, W. F., Jacobson, D. J., McLeod, D. G. and Moul, J. W.: Age-specific reference ranges for serum prostate-specific antigen in black men. New Engl. J. Med., 355: 304, 1996.
21. Lilja, H.: Significance of different molecular forms of serum PSA: the free, noncomplexed form of PSA versus that complexed to alpha-1-antichymotrypsin. Urol. Clin. N. Amer., 20: 681, 1993.
22. Stenman, U. and Oesterling, J. E.: Impact of tumor doubling time (DT) and age-based reference values for PSA on prostate cancer (PCa) screening outcome. J. Urol., part 2, 153: 505A, abstract 1106, 1995.
23. Dugan, J. A., Bostwick, D. G., Myers, R. P., Qian, J., Bergstralh, E. J. and Oesterling, J. E.: The definition and preoperative prediction of clinically insignificant prostate cancer. J.A.M.A., 275: 288, 1996.